Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor

Background: Elevated soluble urokinase plasminogen activator receptor (suPAR) is highly associated with increased risk of diabetic complications. Dapagliflozin is a drug inhibiting the sodium-glucose co-transporter 2 in the kidney to decrease blood glucose, while also decreasing risk of kidney disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Rotbain Curovic, Viktor, Houlind, Morten B., Hansen, Tine W., Eugen-Olsen, Jesper, Laursen, Jens Christian, Eickhoff, Mie K., Persson, Frederik, Rossing, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091812/
https://www.ncbi.nlm.nih.gov/pubmed/35571091
http://dx.doi.org/10.3389/fphar.2022.799915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091812/
https://www.ncbi.nlm.nih.gov/pubmed/35571091
http://dx.doi.org/10.3389/fphar.2022.799915

Ejemplares similares